Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 95005 (TAS-102) + Oxaliplatin in Metastatic Colorectal Cancer
NCT02848443Phase 1Completed
- Sponsor
- Servier
- Start
- May 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC), sponsored by Servier. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Dose Limiting Toxicity at 4 weeks and 7 more. Started May 2016; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02848443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848443.